COMMUNIQUÉS West-GlobeNewswire

Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma
04/11/2026
Ronde-cel achieved a 91% overall response rate and 77% complete response rate; median progression-free survival not reached and estimated 6-month duration of complete response of 92% in 44 patients with 3L+ R/R LBCL in [...]
Phase 1 Data for CITY-FXI, an RNAi Therapeutic Candidate for Thromboembolic Diseases, Selected for Oral Presentation at the 68th ASH Annual Meeting
04/11/2026
Preclinical data supporting CITY-TFR2 for anemia of chronic disease to be presented in a poster session CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY), a clinical-stage [...]
Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026
04/11/2026
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an in- [...]
Corvus Pharmaceuticals Announces Initial Data from Soquelitinib Clinical Trial in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) will be Presented at the 68ᵗʰ American Society for Hematology Annual Meeting & Exposition
04/11/2026
Data shows positive one-year safety and efficacy data from three patients enrolled in ongoing Phase 2 clinical trial being led by researchers at the National Institute of Allergy and Infectious Diseases (NIAID) Safety [...]
Secura Bio Announces Two Duvelisib Presentations on Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma at the 2026 American Society of Hematology Annual Meeting
04/11/2026
Phase 2 PRIMO sub-analysis highlights outcomes with duvelisib in patients with peripheral T-cell lymphoma who proceeded to stem cell transplant Novel topical formulation of duvelisib in cutaneous T-cell lymphoma [...]
Umoja Biopharma Announces Oral Presentation of First UB-VV400 In Vivo CAR T Cell Therapy Clinical Data and Four Total Presentations at the 68th ASH Annual Meeting
04/11/2026
Presentations span UB-VV400 and UB-VV410 clinical data from investigator-initiated trials and trial-in-progress posters for UB-VV400 and UB-VV500 SEATTLE, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja [...]
Atavistik Bio to Highlight Momentum Across Hematology Pipeline with Harmony-HHT Clinical Trial Update and New Preclinical Data from HHT and JAK2 V617F Programs at ASH 2026
04/11/2026
Harmony-HHT trial-in-progress poster to showcase the ongoing Phase 1/2 clinical study of ATV-1601, an investigational oral, AKT1-selective allosteric inhibitor targeting the underlying disease biology of hereditary [...]
Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition
04/11/2026
WELLESLEY HILLS, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that [...]
Kamau Therapeutics Announces First Multi-Patient Clinical Data Showing Precise Correction of the Sickle Cell Mutation and Restoration of Adult Hemoglobin
04/11/2026
All three patients are transfusion-independent with no vaso-occlusive events; predominant adult hemoglobin profile restored, with sickle hemoglobin below 20% beyond six months Data to be featured in an oral presentation [...]
Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026
04/11/2026
New CARTITUDE-4 subgroup analyses provide further insights into durable clinical outcomes with CARVYKTI in earlier-line treatment Updated data to be presented from first-in-human trial of LB2501, an investigational, off [...]
Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting
04/11/2026
Media Release COPENHAGEN, Denmark; November 4, 2026 Twenty-two abstracts underscore the versatility of epcoritamab as monotherapy and in combination across multiple disease subtypes and in earlier lines of therapy Six [...]
TOMI Environmental Solutions, Inc. Announces Recurring Consumable Agreement with Global Eye Health Company
04/11/2026
Combined revenue from two facilities is approximately $750,000 FREDERICK, Md., Nov. 04, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and [...]
OneMedNet Receives Mid Six-Figure Re-Order from Foundation Model Company Developing Radiology Models
04/11/2026
Repeat order underscores demand for full-fidelity data at the scale required to train foundation AI models in radiology MINNEAPOLIS, Nov. 04, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” [...]
SeaStar Medical to Report Third Quarter Financial Results on November 11, 2026
04/11/2026
DENVER, Nov. 04, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure [...]
Eliminating Static Without Electricity - MEC Industries Introduces the Powerless ECO Ionizer
04/11/2026
Powerless ECO Ionizer Eliminates Static Without Electricity SEOUL, South Korea, Nov. 04, 2026 (GLOBE NEWSWIRE) -- MEC Industries introduces the Powerless ECO Ionizer , a static-control device that operates without an [...]
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04/11/2026
BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
Clene Reports Third Quarter 2026 Financial Results and Recent Operating Highlights
04/11/2026
Submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in October 2026 seeking accelerated approval for CNM-Au8 ® in amyotrophic lateral sclerosis (ALS) Completed a $4.0 million registered [...]
AltruBio to Host Virtual R&D Day on ALTB-268 and Ulcerative Colitis on November 11, 2026
04/11/2026
SAN FRANCISCO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- AltruBio Inc. ("AltruBio" or "the Company"), a clinical-stage biotech company developing novel immune modulators to address the unmet need in immunological and [...]
Intelligent Bio Solutions to Present at the Webull Biotech Webinar on November 12
04/11/2026
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today [...]

Pages